Dr Reddy’s launches anti-coagulant drug in US market

New Delhi: Drug major Dr Reddy’s Laboratories Monday announced the launch of anti-coagulant drug Aspirin and extended-release dipyridamole capsules in the US market. The product is a therapeutic equivalent to generic version of Aggrenox (aspirin and extended-release dipyridamole) capsules, the company said in a BSE filing.

Quoting IMS Health data, Dr Reddy’s Laboratories said the Aggrenox brand and generic had US sales of approximately USD 182 million for the most recent 12 months ending in October 2018.

Dr Reddy’s Aspirin and extended-release Dipyridamole capsules is available in 25 mg/200 mg strength with 60 count bottle size. Aggrenox is a trademark of Boehringer lngelheim.

Stock of Dr Reddy’s Laboratories was trading 0.48 per cent lower at Rs 2,591.45 apiece on BSE.

  • Related Posts

    • Pharma
    • June 17, 2025
    • 91 views
    Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

    Bengaluru-based biopharmaceutical firm Biocon on Monday launched a qualified institutions placement (QIP) to raise Rs 4,500 crore. As part of the offering, the firm will issue up to 139 million…

    • Pharma
    • June 17, 2025
    • 96 views
    Zydus Healthcare appoints Swati Dalal MD

    Zydus Lifesciences Ltd on Monday announced the appointment of Swati Dalal as an additional director and Managing Director of its wholly-owned arm Zydus Healthcare Ltd. The board of Zydus Healthcare…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

    Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

    Zydus Healthcare appoints Swati Dalal MD

    Zydus Healthcare appoints Swati Dalal MD

    Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

    Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President – Operations at Mekaguda

    Natco API plant gets one observation from FDA

    Natco API plant gets one observation from FDA